Metabolic Syndrome Patients Have Lower Levels of Adropin When Compared With Healthy Overweight/Obese and Lean Subjects

Somaye Yosaee, Mahmoud Khodadost, Alireza Esteghamati, John R. Speakman, Farzad Shidfar, Mahdiyeh Nasab Nazari, Vida Bitarafan, Kurosh Djafarian*

*Corresponding author for this work

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Metabolic syndrome (MetS), a cluster of cardiometabolic risk factors, is a challenging public health issue. The aim of current study was to test the hypothesis that concentrations of plasma adropin and leptin differ between patients with MetS and comparable age- and sex-matched control groups. This case-control study involved 153 subjects (51 per group). The study group included obese subjects with MetS and the two control groups included weight-matched subjects without MetS (“healthy”: obese) and normal weight subjects without MetS. Body composition parameters were measured using bioelectrical impedance analysis. Plasma levels of adropin, leptin, and their ratio were measured. Leptin was significantly different between obese patients with/without MetS groups and normal weight subjects. Patients with MetS had higher levels of leptin (14 ± 12.4) compared with those without MetS (11.2 ± 9.3 vs. 7 ± 7.1 obese and normal weight without MetS, respectively; p =.002). Compared with healthy obese and normal weight subjects, MetS subjects had lower levels of plasma adropin (p <.001) and a lower plasma adropin to leptin ratio (p <.001), which remained significant when adjusted for body fat mass by analysis of covariance (p <.001). This study demonstrates low levels of adropin are correlated with MetS and hence identify it as a potentially protective agent against MetS development. Variation in adropin levels may partly explain the “healthy obese” phenomenon.

Original languageEnglish
Pages (from-to)426-434
Number of pages9
JournalAmerican Journal of Men's Health
Volume11
Issue number2
Early online date22 Aug 2016
DOIs
Publication statusPublished - 1 Mar 2017

Fingerprint

Leptin
Weights and Measures
Group
study group
public health
Protective Agents
Control Groups
Body Composition
Electric Impedance
Adipose Tissue
Case-Control Studies
Research Design
Public Health

Keywords

  • adropin
  • body composition
  • leptin
  • metabolic syndrome
  • obesity

ASJC Scopus subject areas

  • Health(social science)
  • Public Health, Environmental and Occupational Health

Cite this

Metabolic Syndrome Patients Have Lower Levels of Adropin When Compared With Healthy Overweight/Obese and Lean Subjects. / Yosaee, Somaye; Khodadost, Mahmoud; Esteghamati, Alireza; Speakman, John R.; Shidfar, Farzad; Nazari, Mahdiyeh Nasab; Bitarafan, Vida; Djafarian, Kurosh.

In: American Journal of Men's Health, Vol. 11, No. 2, 01.03.2017, p. 426-434.

Research output: Contribution to journalArticle

Yosaee, Somaye ; Khodadost, Mahmoud ; Esteghamati, Alireza ; Speakman, John R. ; Shidfar, Farzad ; Nazari, Mahdiyeh Nasab ; Bitarafan, Vida ; Djafarian, Kurosh. / Metabolic Syndrome Patients Have Lower Levels of Adropin When Compared With Healthy Overweight/Obese and Lean Subjects. In: American Journal of Men's Health. 2017 ; Vol. 11, No. 2. pp. 426-434.
@article{1b6df5132f1c4db8b01b7dfa2819b40c,
title = "Metabolic Syndrome Patients Have Lower Levels of Adropin When Compared With Healthy Overweight/Obese and Lean Subjects",
abstract = "Metabolic syndrome (MetS), a cluster of cardiometabolic risk factors, is a challenging public health issue. The aim of current study was to test the hypothesis that concentrations of plasma adropin and leptin differ between patients with MetS and comparable age- and sex-matched control groups. This case-control study involved 153 subjects (51 per group). The study group included obese subjects with MetS and the two control groups included weight-matched subjects without MetS (“healthy”: obese) and normal weight subjects without MetS. Body composition parameters were measured using bioelectrical impedance analysis. Plasma levels of adropin, leptin, and their ratio were measured. Leptin was significantly different between obese patients with/without MetS groups and normal weight subjects. Patients with MetS had higher levels of leptin (14 ± 12.4) compared with those without MetS (11.2 ± 9.3 vs. 7 ± 7.1 obese and normal weight without MetS, respectively; p =.002). Compared with healthy obese and normal weight subjects, MetS subjects had lower levels of plasma adropin (p <.001) and a lower plasma adropin to leptin ratio (p <.001), which remained significant when adjusted for body fat mass by analysis of covariance (p <.001). This study demonstrates low levels of adropin are correlated with MetS and hence identify it as a potentially protective agent against MetS development. Variation in adropin levels may partly explain the “healthy obese” phenomenon.",
keywords = "adropin, body composition, leptin, metabolic syndrome, obesity",
author = "Somaye Yosaee and Mahmoud Khodadost and Alireza Esteghamati and Speakman, {John R.} and Farzad Shidfar and Nazari, {Mahdiyeh Nasab} and Vida Bitarafan and Kurosh Djafarian",
note = "Acknowledgements: The research group would like to thank all subjects who took part in the current study. Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.",
year = "2017",
month = "3",
day = "1",
doi = "10.1177/1557988316664074",
language = "English",
volume = "11",
pages = "426--434",
journal = "American Journal of Men's Health",
issn = "1557-9883",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Metabolic Syndrome Patients Have Lower Levels of Adropin When Compared With Healthy Overweight/Obese and Lean Subjects

AU - Yosaee, Somaye

AU - Khodadost, Mahmoud

AU - Esteghamati, Alireza

AU - Speakman, John R.

AU - Shidfar, Farzad

AU - Nazari, Mahdiyeh Nasab

AU - Bitarafan, Vida

AU - Djafarian, Kurosh

N1 - Acknowledgements: The research group would like to thank all subjects who took part in the current study. Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Metabolic syndrome (MetS), a cluster of cardiometabolic risk factors, is a challenging public health issue. The aim of current study was to test the hypothesis that concentrations of plasma adropin and leptin differ between patients with MetS and comparable age- and sex-matched control groups. This case-control study involved 153 subjects (51 per group). The study group included obese subjects with MetS and the two control groups included weight-matched subjects without MetS (“healthy”: obese) and normal weight subjects without MetS. Body composition parameters were measured using bioelectrical impedance analysis. Plasma levels of adropin, leptin, and their ratio were measured. Leptin was significantly different between obese patients with/without MetS groups and normal weight subjects. Patients with MetS had higher levels of leptin (14 ± 12.4) compared with those without MetS (11.2 ± 9.3 vs. 7 ± 7.1 obese and normal weight without MetS, respectively; p =.002). Compared with healthy obese and normal weight subjects, MetS subjects had lower levels of plasma adropin (p <.001) and a lower plasma adropin to leptin ratio (p <.001), which remained significant when adjusted for body fat mass by analysis of covariance (p <.001). This study demonstrates low levels of adropin are correlated with MetS and hence identify it as a potentially protective agent against MetS development. Variation in adropin levels may partly explain the “healthy obese” phenomenon.

AB - Metabolic syndrome (MetS), a cluster of cardiometabolic risk factors, is a challenging public health issue. The aim of current study was to test the hypothesis that concentrations of plasma adropin and leptin differ between patients with MetS and comparable age- and sex-matched control groups. This case-control study involved 153 subjects (51 per group). The study group included obese subjects with MetS and the two control groups included weight-matched subjects without MetS (“healthy”: obese) and normal weight subjects without MetS. Body composition parameters were measured using bioelectrical impedance analysis. Plasma levels of adropin, leptin, and their ratio were measured. Leptin was significantly different between obese patients with/without MetS groups and normal weight subjects. Patients with MetS had higher levels of leptin (14 ± 12.4) compared with those without MetS (11.2 ± 9.3 vs. 7 ± 7.1 obese and normal weight without MetS, respectively; p =.002). Compared with healthy obese and normal weight subjects, MetS subjects had lower levels of plasma adropin (p <.001) and a lower plasma adropin to leptin ratio (p <.001), which remained significant when adjusted for body fat mass by analysis of covariance (p <.001). This study demonstrates low levels of adropin are correlated with MetS and hence identify it as a potentially protective agent against MetS development. Variation in adropin levels may partly explain the “healthy obese” phenomenon.

KW - adropin

KW - body composition

KW - leptin

KW - metabolic syndrome

KW - obesity

UR - http://www.scopus.com/inward/record.url?scp=85012963388&partnerID=8YFLogxK

U2 - 10.1177/1557988316664074

DO - 10.1177/1557988316664074

M3 - Article

AN - SCOPUS:85012963388

VL - 11

SP - 426

EP - 434

JO - American Journal of Men's Health

JF - American Journal of Men's Health

SN - 1557-9883

IS - 2

ER -